Enveric Biosciences, Inc. Gross Profit

• Enveric Biosciences, Inc. showed a decrease of -9.3% in Gross Profit from 2018 to 2019.
• This data is from Enveric Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2020.
• XBRL data for this metric is available from 2016 to 2019 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2010: $0.00 | Q2 2011: $0.00 | Q1 2015: $1.12 million | Q2 2015: $982.7 thousand | Q3 2015: $1.44 million | Q1 2016: $1.65 million | Q2 2016: $1.52 million | Q3 2016: $1.70 million | Q1 2017: $3.30 million | Q2 2017: $2.33 million | Q3 2017: $2.56 million | Q1 2018: $2.34 million | Q2 2018: $2.39 million | Q3 2018: $2.35 million | Q1 2019: $2.14 million | Q2 2019: $2.38 million | Q3 2019: $1.90 million | Q1 2020: $1.88 million | Q2 2020: $1.82 million | Q3 2020: $1.89 million.
• Over the full 4 years of available data (2016 to 2019), Enveric Biosciences, Inc.'s Gross Profit has grown by 17.6%.
• Historical annual values: Fiscal year 2019: $8.15 million | Fiscal year 2018: $8.98 million | Fiscal year 2017: $10.24 million | Fiscal year 2016: $6.93 million.
• Data sourced from SEC EDGAR public filings as of August 4, 2026.

Last verified: August 4, 2026